July 10, 2023
3 min watch
Save
VIDEO: Cyto-KIK trial examines cabozantinib and cytoreductive nephrectomy
In this video, Farshid Sadeghi, MD, discussed data from the Cyto-KIK trial on renal cell carcinoma at American Urological Association Annual Meeting.
Sadeghi, a clinical assistant professor at City of Hope Phoenix, highlighted the study, which examined patients with metastatic renal cell carcinoma being treated by a combination therapy of cabozantinib (Cabometyx, Exelixis) and immunotherapy, undergoing cytoreductive nephrectomy, and subsequently resuming the combination therapy.
“For us as surgeons it’s useful to know that after stopping cabozantinib for 2 weeks, patients can be taken to the operating group,” Sadeghi said.
Reference:
- Runcie K, et al. Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial. Presented at: American Urological Association Annual Meeting; April 28-May 1, 2023; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Disclosures:
Sadeghi reports no relevant financial disclosures.
Read more about